Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bimekizumab in Chinese Adult Study Participants With Moderate to Severe Plaque Psoriasis
NCT06011733Phase 3Completed
- Sponsor
- UCB
- Start
- Oct 2023
- Primary completion
- Feb 2025
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of bimekizumab in plaque psoriasis, sponsored by UCB. Started Oct 2023; status: completed.
02
Drugs
bimekizumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT06011733.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06011733.